| __timestamp | Amgen Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4297000000 | 79696000 |
| Thursday, January 1, 2015 | 4070000000 | 93236000 |
| Friday, January 1, 2016 | 3840000000 | 150842000 |
| Sunday, January 1, 2017 | 3562000000 | 150643000 |
| Monday, January 1, 2018 | 3737000000 | 150252000 |
| Tuesday, January 1, 2019 | 4116000000 | 140804000 |
| Wednesday, January 1, 2020 | 4207000000 | 34236000 |
| Friday, January 1, 2021 | 4819000000 | 35672000 |
| Saturday, January 1, 2022 | 4434000000 | 66607000 |
| Sunday, January 1, 2023 | 4784000000 | 76363000 |
| Monday, January 1, 2024 | 5964000000 | 79048000 |
Unleashing the power of data
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of innovation and future growth. Over the past decade, Amgen Inc. and Halozyme Therapeutics, Inc. have showcased contrasting strategies in their R&D investments. Amgen, a titan in the industry, consistently allocated substantial resources, with an average annual R&D expenditure of approximately $4.2 billion from 2014 to 2023. This represents a steady commitment to innovation, peaking in 2021 with a 35% increase from its lowest point in 2017.
Conversely, Halozyme Therapeutics, a smaller player, demonstrated a more volatile R&D spending pattern, averaging around $98 million annually. Notably, their highest investment occurred in 2016, marking a 78% increase from 2014. This disparity highlights the diverse approaches within the biotech sector, where giants like Amgen leverage scale, while nimble firms like Halozyme adapt swiftly to market demands.
Eli Lilly and Company or Halozyme Therapeutics, Inc.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Amgen Inc. and Bristol-Myers Squibb Company
Research and Development Expenses Breakdown: Amgen Inc. vs Madrigal Pharmaceuticals, Inc.
Gross Profit Trends Compared: Amgen Inc. vs Halozyme Therapeutics, Inc.
Amgen Inc. or ACADIA Pharmaceuticals Inc.: Who Invests More in Innovation?
Research and Development Investment: Bio-Techne Corporation vs Halozyme Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Halozyme Therapeutics, Inc. and Madrigal Pharmaceuticals, Inc.
Analyzing R&D Budgets: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc.
Analyzing R&D Budgets: Halozyme Therapeutics, Inc. vs Soleno Therapeutics, Inc.
Comparing Innovation Spending: Halozyme Therapeutics, Inc. and MannKind Corporation
Comparing Innovation Spending: Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Research and Development: Comparing Key Metrics for Halozyme Therapeutics, Inc. and Amphastar Pharmaceuticals, Inc.